文献速递帕金森病与运动障碍

改善病情抗风湿药与帕金森病风险:类风湿关节炎患者的巢式病例对照研究

Disease-Modifying Antirheumatic Drugs and Risk of Parkinson Disease: Nested Case-Control Study of People With Rheumatoid Arthritis.
PubMed 文献 · Neurology · 2022-01-21

在芬兰帕金森病队列中开展的全国性巢式病例对照研究,纳入315例帕金森病病例和1571例匹配对照,评估改善病情抗风湿药与帕金森病风险的关联。多数药物与帕金森病风险无关,仅氯喹/羟氯喹与风险降低相关(调整OR 0.74,95%CI 0.56-0.97)。作者认为类风湿关节炎患者帕金森病风险较低不能由抗风湿药使用解释。

要点

  • 在类风湿关节炎患者中,多数改善病情抗风湿药与帕金森病风险无关联。
  • 氯喹/羟氯喹与帕金森病风险降低相关(调整OR 0.74,95%CI 0.56-0.97)。
  • 作者认为类风湿关节炎患者帕金森病风险较低不能由抗风湿药使用解释。

核心结论

  • 作者认为类风湿关节炎患者帕金森病风险较低不能由改善病情抗风湿药使用解释,因为这类药物总体上未改变类风湿关节炎患者的帕金森病风险。
  • 氯喹/羟氯喹与帕金森病风险降低的关联及其可能机制应进一步研究。

研究设计与样本

  • 在芬兰帕金森病(FINPARK)队列(包含22189名1996至2015年确诊的临床验证帕金森病患者)内开展的全国性巢式病例对照研究。
  • 纳入1999至2015年确诊帕金森病且帕金森病诊断前超过3年确诊类风湿关节炎的病例,按年龄、性别、类风湿关节炎病程和地区与最多7名对照匹配。
  • 共纳入315例帕金森病病例和1571例匹配对照,多数(>60%)为女性。
  • 采用条件logistic回归调整混杂因素,暴露与结局之间设3年滞后期。

主要发现

  • 匹配日期时类风湿关节炎中位病程:对照11.6年,病例12.6年。
  • 除氯喹/羟氯喹外,改善病情抗风湿药使用与帕金森病风险无关(设3年滞后期)。
  • 氯喹/羟氯喹与帕金森病风险降低相关(调整OR 0.74,95%CI 0.56-0.97)。
  • 柳氮磺吡啶、甲氨蝶呤、金制剂和免疫抑制剂等其他改善病情抗风湿药与帕金森病无关。

关键数值与推荐

  • 本研究提供II级证据:在类风湿关节炎患者中,使用改善病情抗风湿药时仅氯喹/羟氯喹与帕金森病发生风险潜在降低相关(调整OR 0.74,95%CI 0.56-0.97)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Epidemiologic studies have suggested a link between rheumatoid arthritis and Parkinson disease (PD). Disease-modifying antirheumatic drugs (DMARDs) might explain this association. The aim of this work was to evaluate the association between DMARDs and risk of PD in persons with rheumatoid arthritis. METHODS: This nested nationwide case-control study was conducted within the Finnish Parkinson's Disease (FINPARK) cohort, which includes 22,189 Finnish persons with clinically verified PD diagnosed in 1996 to 2015. The cases had recorded diagnosis of PD in the Special Reimbursement Register and had no exclusion diagnoses with symptoms that may be confused with PD within 2 years of PD diagnosis. This study included cases with PD diagnosed during 1999 to 2015 and rheumatoid arthritis diagnosed >3 years before PD. Rheumatoid arthritis was identified from the Finnish Care Register for Health Care and Special Reimbursement Register. Cases were matched with up to 7 controls by age, sex, duration of rheumatoid arthritis, and region. DMARDs were categorized into 5 classes, and data on purchased prescriptions were identified from the Prescription Register since 1995. Associations were studied with conditional logistic regression adjusted for confounders. RESULTS: Altogether, 315 cases with PD and 1,571 matched controls were included. The majority (>60%) were women, and the median duration of rheumatoid arthritis on matching date was 11.6 years for controls and 12.6 years for cases. Use of DMARDs was not associated with risk of PD with a 3-year lag period applied between exposure and outcome except chloroquine/hydroxychloroquine, which associated with decreased risk (adjusted odds ratio [OR] 0.74, 95% confidence interval [CI] 0.56-0.97). Other DMARDs, including sulfasalazine, methotrexate, gold preparations, and immunosuppressants, were not associated with PD. DISCUSSION: Our results suggest that the lower risk of PD in people with rheumatoid arthritis is not explained by DMARD use because these drugs in general did not modify the risk of PD among persons with rheumatoid arthritis. Association between chloroquine/hydroxychloroquine and lower risk of PD and the possible underlying mechanisms should be further investigated. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that in individuals with rheumatoid arthritis using DMARDs, only chloroquine/hydroxychloroquine was associated with a potentially decreased risk of developing PD (adjusted OR 0.74, 95% CI 0.56-0.97).

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Paakinaho A, Koponen M, Tiihonen M, et al. Disease-Modifying Antirheumatic Drugs and Risk of Parkinson Disease: Nested Case-Control Study of People With Rheumatoid Arthritis. Neurology. 2022. PMID: 35064025. doi:10.1212/WNL.0000000000013303

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。